SM
AEGR

Sabby Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Sabby Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,820
Closed -$12.9M – 297
2013
Q4 		$12.9M Sell
1,820
-1,259
-41% -$96.3K 0.82% 30
2013
Q3 		$26.4M Buy
3,079
+709
+30% +$60.1K 1.72% 15
2013
Q2 		$15M Buy
+2,370
New +$126K 1% 24

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sabby Management's AEGR Position: Q2 2014 in Review

Sabby Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 34,420 shares — an estimated $1.28M sold.

Sabby Management first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $37.6M in Q2 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • Sabby Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Sabby Management sold 34,420 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $1.28M.
  • Sabby Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Sabby Management's Aegerion Pharmaceuticals position peaked at $37.6M in Q2 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.